Trial Profile
A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of Macitentan at Steady State on the Pharmacokinetics of Riociguat in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Sep 2019
Price :
$35
*
At a glance
- Drugs Macitentan (Primary) ; Riociguat (Primary)
- Indications Congenital heart defects; Eisenmenger complex; Heart failure; Portal hypertension; Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 24 Sep 2019 Results assessing effect of Macitentan on the pharmacokinetics of the breast cancer resistance protein substrate Rosuvastatin in healthy male subjects published in the Clinical Drug Investigation
- 07 Feb 2018 Status changed from recruiting to completed.
- 08 Jan 2018 Status changed from not yet recruiting to recruiting.